Moreover, IGFBP2 was associated with significantly worse event-free survival and overall survival in patients with AML (GSE6891, n = 344, log-rank test, p < 0.001 and p = 0.006, respectively; Additional file 1: Fig. S5F) and t(8;21) AML (n = 26, log-rank test, p = 0.045 and p = 0.061, respectively; Fig. 5G). This evidence concerns the gene IGFBP2 and acute myeloid leukemia.